Literature DB >> 30008100

A Universal Tumor-Specific Promoter for Cancer Gene Therapy.

I V Alekseenko1,2, V V Pleshkan3,4, A V Sass3, O B Filyukova3, E V Snezhkov3, E D Sverdlov3,4.   

Abstract

An artificial double tandem tumor-specific promoter based on survivin and human telomerase reverse transcriptase gene promoters was constructed. Studies in in vitro and ex vivo therapeutic systems showed that the designed promoter exhibits a high activity in tumor cells, which is comparable to the activity of the CMV constitutive promoter.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30008100     DOI： 10.1134/S1607672918030092

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


  11 in total

Review 1.  Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?

Authors:  Kevin S Clive; Josh A Tyler; G Travis Clifton; Jarrod P Holmes; Elizabeth A Mittendorf; Sathibalan Ponniah; George E Peoples
Journal:  Expert Rev Vaccines       Date:  2010-05       Impact factor: 5.217

2.  Bystander killing effect of tymidine kinase gene-transduced adult bone marrow stromal cells with ganciclovir on malignant glioma cells.

Authors:  Kentaro Mori; Junko Iwata; Masahiro Miyazaki; Hideo Osada; Yuichi Tange; Takuji Yamamoto; Yasuhisa Aiko; Masaru Tamura; Toshihiko Shiroishi
Journal:  Neurol Med Chir (Tokyo)       Date:  2010       Impact factor: 1.742

3.  Delivery of hypoxia and glioma dual-specific suicide gene using dexamethasone conjugated polyethylenimine for glioblastoma-specific gene therapy.

Authors:  Hyun Ah Kim; Jin Hyeong Park; Na Yi; Minhyung Lee
Journal:  Mol Pharm       Date:  2014-02-03       Impact factor: 4.939

4.  Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas.

Authors:  Armen Azatian; Hong Yu; Wande Dai; Fiona I Schneiders; Natalia K Botelho; Reginald V N Lord
Journal:  J Gastrointest Surg       Date:  2009-03-10       Impact factor: 3.452

5.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

Authors:  S M Freeman; C N Abboud; K A Whartenby; C H Packman; D S Koeplin; F L Moolten; G N Abraham
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

Review 6.  Clinical development of gene therapy for colorectal cancer.

Authors:  David Kerr
Journal:  Nat Rev Cancer       Date:  2003-08       Impact factor: 60.716

7.  Concordant expression of the telomerase-associated genes in non-small cell lung cancer.

Authors:  C-P Hsu; J Miaw; J-Y Hsia; S-E Shai; C-Y Chen
Journal:  Eur J Surg Oncol       Date:  2003-09       Impact factor: 4.424

8.  A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.

Authors:  Seiji Yamamoto; Tomoki Yamano; Maki Tanaka; Dave S B Hoon; Sonshin Takao; Ryuichi Morishita; Takashi Aikou; Yasufumi Kaneda
Journal:  Cancer Gene Ther       Date:  2003-03       Impact factor: 5.987

9.  Hybrid promoters directed tBid gene expression to breast cancer cells by transcriptional targeting.

Authors:  Samila Farokhimanesh; Fatemeh Rahbarizadeh; Mohammad J Rasaee; Abbas Kamali; Baratali Mashkani
Journal:  Biotechnol Prog       Date:  2010 Mar-Apr

10.  Activity of the upstream component of tandem TERT/survivin promoters depends on features of the downstream component.

Authors:  Irina V Alekseenko; Victor V Pleshkan; Eugene P Kopantzev; Elena A Stukacheva; Igor P Chernov; Tatyana V Vinogradova; Eugene D Sverdlov
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240
View more
  1 in total

1.  Searching for Promoters to Drive Stable and Long-Term Transgene Expression in Fibroblasts for Syngeneic Mouse Tumor Models.

Authors:  Dina V Antonova; Irina V Alekseenko; Anastasiia K Siniushina; Alexey I Kuzmich; Victor V Pleshkan
Journal:  Int J Mol Sci       Date:  2020-08-24       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.